Adamas Pharmaceuticals Gross Profit

Adamas Pharmaceuticals (ADMS) currently reports a gross profit of $86M as of September 2021. That compares with $68M in the prior-year period — up 26.8% year over year. That is below the Healthcare sector average of $65B. Use the charts on this page to explore Adamas Pharmaceuticals's gross profit history and peer comparisons.

Adamas Pharmaceuticals's gross profit increased from $68M to $86M — a 26.8% year-over-year increase (period ending September 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Adamas Pharmaceuticals's gross profit of $86M is lower than the Healthcare sector average of $65B. That is roughly 99.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Adamas Pharmaceuticals reported $86M in gross profit as of September 2021. That compares with $68M in the prior-year period — up 26.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $86M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $65B. From there, open related valuation or income-statement pages for Adamas Pharmaceuticals, and consider following ADMS for alerts when major investors trade the stock.